Aim: To determine the prevalence of psoriasis in an IBD cohort with reference to clinical characteristics and anti-TNFa use. Methods: Patients with psoriasis and IBD were retrospectively identified from the IBD database at Tallaght Hospital from 2000 to 2015. Pertinent clinical data were obtained from patients notes including anti-TNFa exposure. Prevalence rates of genuine and reactive psoriasis were calculated and compared using Student's T-test. A P values of <0.05 was considered significant. Results: In total, 1384 IBD patients were identified. The overall prevalence rate of IBD and psoriasis was 2.4% (n ¼ 33), with 1.8% (n ¼ 25) in the Crohn's disease group and 0.6% (n ¼ 8) in the ulcerative colitis group. Within the psoriasis group, 24% (n ¼ 8 of 33) had reactive psoriasis. The prevalence rates of psoriasis in the non-biological and biological cohorts were similar 2.5% (25 of 981) and 2% (8 of 403), respectively. There was no significant association with reactive psoriasis and disease type. There was a trend towards higher rates of reactive psoriasis Adalimumab users, 3.6% (6 of 166) vs. 0.8% (2 of 237), OR ¼ 4.283, P ¼ 0.077, 95% CI 0.854-21.483 in infliximab users. In addition, in our cohort, smoking was not associated with any form of psoriasis in IBD, OR ¼ 1.377, 95% CI 0.061-3.087, P ¼ 0.437. Conclusion: In our large study, the prevalence rate of reactive psoriasis was similar to the background rate of psoriasis in the overall IBD cohort (2.0 vs. 2.4%). A 2% prevalence rate represents a common adverse event that clinicians should be aware of.
Introduction
Tumour necrosis factor alpha (TNFa) is a pro-inflammatory cytokine that is implicated in the pathogenesis of a range of chronic inflammatory conditions including IBD, psoriasis, ankylosing spondylitis and rheumatoid arthritis. The development of TNFa antagonists such as infliximab and adalimumab has led to a revolution in the treatment of IBD. To date, a number of randomized controlled trials have demonstrated that early management with anti-TNFa therapy improves long-term outcomes in patients with IBD by inducing early remission and mucosal healing. [1] [2] [3] Although considered safe agents, some of the potential side-effects include opportunistic infections, increased risk of lymphoma, demyelinating disease and congestive heart failure. In recent years, an increasing number of cases of psoriasis related to anti-TNFa therapy in IBD patients have been reported. This appears paradoxical as TNFa is a pivotal molecule in the pathophysiology of psoriatic skin lesions and both infliximab and adalimumab have been shown to be effective therapeutic options for patients with moderate-tosevere psoriasis. 4, 5 The underlying pathogenic mechanisms of reactive psoriasis in IBD patients have yet to be elucidated, although several theories have been hypothesized. TNFa plays an immune-regulatory role by decreasing interferon-a expression via inhibition of maturation of plasmacytoid dendritic cells. It has therefore been postulated that anti-TNFa induces the recruitment of T cells and the secretion of pro-inflammatory cytokines IL12 and IL23 by inhibiting this suppression of Interferon-a expression, which is responsible for the changes observed in the dermis of patients with psoriasis. 6, 7 This proposed theory is further affirmed by a recent study by Tillack et al. 8 showing for the first time that
Ustekinumab (IL12/IL23 inhibitor) is effective in CD patients with severe anti-TNFa induced psoriasiform skin lesions. However, the fact that only some patients develop this phenomenon of reactive psoriasis means that the precise mechanism leading to the development of this side effect remains unclear and warrants further exploration.
Aims
We wished to assess the prevalence of psoriasis in a large IBD cohort with reference to clinical characteristics and anti-TNFa use.
Materials and methods
This is a retrospective chart review involving the collection of existing data, therefore, not requiring ethical approval. All details that might disclose the identity of the subjects under this study was anonymized. 
Results

Patient demographics
A total of 1348 IBD patients were identified from the IBD database at Tallaght Hospital from 2000 to 2015, of which 665 (48%) were females. In our IBD cohort, 483 (35%) patients had UC and 901 (65%) CD. Overall, 261 (19%) ever smoked. In all, 403 (29%) patients had received an anti-TNFa agent with 237 (59%) and 166 (41%) on infliximab and adalimumab, respectively. The prevalence rate of psoriasis in the non-anti TNFa exposed and anti-TNFa exposed cohorts were similar 2.5% (25 of 981) and 2% (8 of 403), respectively. As expected and in keeping with known epidemiological data, a higher number, 189 (21%) of the CD group smoked compared with 72 (15%) in the UC cohort, P ¼ 0.0001, 95% CI 0.15-0.21. Table 1 shows the characteristics of IBD population included in this study.
All psoriasis
The overall prevalence rate of psoriasis, i.e. including both genuine and reactive psoriasis in our IBD cohort was 2.4% (n ¼ 33). Of the 33 patients with psoriasis, the mean age was 46 years (range 18-66), and 13 (39%) females. In all, 15 of the 33 (45%) patients with psoriasis were anti-TNF therapy naïve. Of the remaining 18 (55%) cases of psoriasis (n ¼ 33) who were on an anti-TNF; 8 (44%) had reactive psoriasis group, i.e. developed psoriasis post exposure to anti-TNF therapy and the remaining 10 had genuine pre-existing psoriasis, i.e. had psoriasis prior to commencement of anti-TNF therapy'. While more men had IBD and psoriasis, there was no significant association between genders an increased risk of overall psoriasis, 2.7% (20 of 719) men vs. 1.9% (13 of 665) women. Of interest, all psoriasis occurred more frequently in patients with UC, odds ratio (OR) ¼ 5.82, P < 0.001, 95% CI ¼ 2.61-13.02, 25 of 483 patients (5.2%) vs. 8 of 901 CD patients (0.89%).
Genuine and reactive psoriasis
When we further analysed the two forms of psoriasis in this IBD cohort, genuine (patients who had psoriasis prior to exposure to anti-TNF therapy and psoriasis patients who were anti-TNF therapy naive) and reactive (patients developing psoriasis post exposure to anti-TNF therapy), we found 25 (76%) patients had genuine psoriasis and 8 (24%) had reactive psoriasis. It was While there were more men with reactive psoriasis, this was not statistically significant. There was a trend towards higher rates of reactive psoriasis in adalimumab users which was 3.6% (6 of 166) vs. 0.8% (2 of 237), OR ¼ 4.28, P ¼ 0.077, 95% CI 0.85-21.48 in the infliximab cohort. However, overall relatively more CD patients, 44 vs. 31% were prescribed adalimumab, P ¼ 0.02, 95% CI 0.02-0.25, which may account for this finding. In all, four of the adalimumab patients were on a 40-mg fortnightly dosing regime and two patients on a 40-mg weekly dosing regimen. In the infliximab group, both patients were on a 8-weekly dosing regimen of 5 mg/kg. Table 2 shows the prevalence rates and clinical characteristics of subjects with psoriasis and IBD.
Discussion
This study examined the prevalence of genuine and reactive psoriasis within a large IBD cohort (n ¼ 1348) of whom 29% (403) had been treated with an anti-TNFa agent. In our study, 2.4% of IBD patients also had psoriasis. Of note UC was a specific risk factor for overall psoriasis (OR ¼ 5.82). This may be accounted for by the different cytokine profile between UC and CD, based on previous studies whereby there is a preponderance of Th2 cytokines (IL-5 and IL-13) in UC. 9 When we further explored the two forms on psoriasis in this study, genuine and reactive, we found that within 403 IBD patients who were commenced on an anti-TNFa agent, 2% (n ¼ 8) developed reactive psoriasis. This was not statistically different from the background rate of psoriasis in our IBD cohort of 2.4% (33 of 1384). Considering both are TNFa-mediated diseases, the development of psoriasis after initiation of anti-TNFa in IBD may simply reflect the natural history of both conditions. However, it remains a possibility that treatment with an antiTNFa therapy may trigger the psoriatic lesions in susceptible patients. The first reported case of reactive psoriasiform lesions in patients with CD treated with infliximab was in 2004. been noted that the prevalence of reactive psoriasis in patients treated with anti-TNFa ranges from 0.6 to 5.3%, and varies between population studied. 13 More recently, Tillack et al. 8 had reported an incidence proportion of 5% in 434 anti-TNFa treated patients with IBD over an 18-month period. Our overall prevalence rate of 2% in 403 anti-TNFa-treated patients may reflect the retrospective study design which is reliant on self-reporting and appropriate documentation of psoriasis. As such our study is likely to under estimate the true prevalence. However, this may reflect a more clinically relevant disease. Based on this longitudinal data, our incidence rate of reactive psoriasis is 1.3% per 1000 patient years. Our data suggest that subjects with UC were more likely to develop reactive psoriasis although not significant. Contrary to previous studies, smoking was not associated with any form of psoriasis. 8, 10 Similarly, we found a trend towards a higher rate of reactive psoriasis in patients treated with Adalimumab, although again more CD patients received this agent and likely explain this finding. The small numbers in each group limit the further interpretation of these findings but suggest the identification of an at risk group is possible and could hint at underlying differences in aetiology, which warrant further investigation in a prospective study. Of interest, 4 (50%) patients with reactive psoriasis were on dual/combined anti-TNFa and azathioprine. There have been suggestions that combination therapy reduces immunogenicity associated with anti-TNFa agents. However, as the effect on the development of reactive psoriasis in our data is unclear, it would appear not to be a useful therapeutic strategy in at risk groups.
The mechanism leading to the induction or exacerbation of psoriatic lesions by anti-TNFa antagonists is not clear. 14, 15 The relationship between raised interferon alpha (IFN-a) levels and reduction in TNFa levels seems to be the most widely accepted hypothesis. 14, 16, 17 Plasmacytoid dendritic cells, which are normally downregulated by TNFa, appear to induce psoriasis through IFN-a production. These cells infiltrate the skin and produce IFN-a during the initial phase of psoriasis. Therefore, inhibiting TNFa with administration of a biological agent may result in a surge in IFN-a production, therefore inducing or exacerbating psoriasis.
12
There are no current established management guidelines for IBD patients who develop this paradoxical phenomenon of psoriasis with anti-TNF use. Due to the retrospective nature of this study, we are unable to provide data in relation to management and progress of the eight patients who developed reactive psoriasis. It is reasonable to continue the use of anti-TNF therapy for mild-skin lesions and to use topical therapy (corticosteroids, keratolytics and vitamin D analogs). According to Collamer's algorithm, patients with psoriasis covering <5% of body surface area should be treated with topical treatments and for those with lesions affecting >5% of body surface area and palmoplantar type of psoriasis, topical therapies, occlusive therapy to the palms and soles, and UV phototherapy should be considered. 18 For those who show a lack of response to these treatments, switching to an Anti-IL-12/IL-239 antibody (Ustekinumab) therapy can be considered and has been shown to be effective by Tillack et al. 8 for the management of both the psorasiform lesions as well as the primary autoimmune condition of IBD. Despite the overall limitations of this study and the relatively low prevalence rate of reactive psoriasis in general, a frequency of 2-5% does represent a significant clinical adverse event and warrants specific attention from treating clinicians. 
Conclusion
In conclusion, the paradoxical occurrence of psoriasis in IBD patients on an anti-TNFa agent remains an unusual but well acknowledged entity. In our large study, the prevalence rate of reactive psoriasis was similar to the background rate of psoriasis in the overall IBD cohort (2.0 vs. 2.4%). Our data suggest that subjects with UC were more likely to develop reactive psoriasis although not significant. A 2% prevalence rate represents a common adverse event, which clinicians should be aware of. However, further work to better elucidate at risk groups, the immunopathogenic mechanism and to identify suitable therapeutic options should anti-TNFa therapy need to be withdrawn is required.
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